3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Ayse McCracken of Ignite Healthcare Network, Paul Cherukuri of Rice University, and Oyetewa Oyerinde of Baylor College of Medicine. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from health care to academia — recently making headlines in Houston innovation.

Ayse McCracken, founder of Ignite Healthcare Network

Ayse McCracken, founder of Ignite Healthcare Network, joins the Houston Innovators Podcast to discuss how she's growing her impact on female health tech founders. Photo via LinkedIn

With a decades-long career in health care, Ayse McCracken's most recent professional chapter has been laser focused on finding, supporting, and accelerating female-founded startups in health tech with her nonprofit, Ignite Healthcare Network.

Originally founded in 2017 as a pitch competition, Ignite has evolved to become an active and integral program for female health tech entrepreneurs. Ninety-one founders have graduated from Ignite and gone on to raise over $550 million in funding for their ventures. Currently, Ignite has 19 women in its 2023 cohort, which concludes November 9 with the annual Fire Pitch competition.

"Having an impact in the health care industry and finding solutions is important to me," McCracken says of her passion for Ignite on this week's episode of the Houston Innovators Podcast. "The second aspect of that is there are so many women in health care, and yet you don't see them in leadership roles." Read more.

Paul Cherukuri, vice president of innovation at Rice University

Paul Cherukuri, vice president of innovation at Rice University, has had a busy week. Photo via Rice.edu

If it's seemed like a lot has been happening on Rice University campus this month, it's because it has. This week, Paul Cherukuri, Rice’s vice president for innovation hosted an event announcing the university's Biotech Launch Pad, a new accelerator focused on commercializing health care innovations.

“The Biotech Launch Pad is the first in a series of Rice Moonshots that are hyper-focused on building a ‘speed and scale’ innovation ecosystem across Houston," Cherukuri says. "We at Rice are committed towards driving the Biotech Launch Pad in collaboration with our partners within the Texas Medical Center and the new Helix Park campus.” Read more.

The university also recently announced:

     
  • The Rice University Office of Innovation's newly established the One Small Step Grant program that will provide funding to faculty working on "promising projects with commercial potential." Read more.
  • The opening of the Ralph S. O’Connor Building for Engineering and Science, the university's largest core campus research facility. The 250,000-square-foot building is the new home for four key research areas at Rice: advanced materials, quantum science and computing, urban research and innovation, and the energy transition. The university aims for the space to foster collaboration and innovation between the disciplines. Read more.

Oyetewa Oyerinde, leader of the Skin of Color Clinic and assistant professor of dermatology at Baylor College of Medicine

The Skin of Color Clinic is devoted to the unique needs of patients of all ethnicities. Photo courtesy of BCM

All skin is created equal, but not all skin behaves the same. It’s with this in mind that Baylor Medicine Dermatology has announced the debut of its newest office.

The Skin of Color Clinic is located inside the Jamail Specialty Care Center and is devoted to the unique needs of patients of all ethnicities.

The leader of the Skin of Color Clinic is assistant professor of dermatology, Oyetewa Oyerinde. Dr. Oyerinde, a Howard University and University of Illinois at Chicago College of Medicine alum, completed her residency training at Harvard University, where she made it to the role of chief resident in her final year.

“I am excited to lead a clinic that addresses skin issues commonly found in underserved populations,” Oyerinde says in a news release. “I want people in Houston to know that there is a place where an expert will know how to care for their specific needs.” Read more.

The Skin of Color Clinic is devoted to the unique needs of patients of all ethnicities. Photo courtesy of BCM

Baylor Medicine opens innovatively inclusive dermatology center in Houston

skin care for all

All skin is created equal, but not all skin behaves the same. It’s with this in mind that Baylor Medicine Dermatology has announced the debut of its newest office.

The Skin of Color Clinic is located inside the Jamail Specialty Care Center and is devoted to the unique needs of patients of all ethnicities.

The leader of the Skin of Color Clinic is assistant professor of dermatology, Oyetewa Oyerinde. Dr. Oyerinde, a Howard University and University of Illinois at Chicago College of Medicine alum, completed her residency training at Harvard University, where she made it to the role of chief resident in her final year.

“I am excited to lead a clinic that addresses skin issues commonly found in underserved populations,” Oyerinde says in a news release. “I want people in Houston to know that there is a place where an expert will know how to care for their specific needs.”

The leader of the Skin of Color Clinic is assistant professor of dermatology, Oyetewa Oyerinde. Photo via bcm.edu

Patients who identify as Black, African American, Latinx, Asian, or Native American all have different skin with varying requirements, which the Skin of Color Clinic will address in a culturally sensitive and competent manner. An awareness that some conditions affect people with darker skin tones differently than people with light skin tones informs the clinic’s work, as does the fact that there are also some diseases that disproportionately affect people of color.

Dr. Oyerinde specializes in issues including hyper- or hypopigmentation, scarring and non-scarring hair loss, acne keloidalis nuchae, and keloids. Meanwhile, Dr. Zeena Nawas will lead the cosmetic wing of the Skin of Color Clinic. Her areas of expertise include chemical peels, laser hair removal and DPN, and skin tag/seborrheic keratosis removal.

“Dr. Oyerinde will excel as the director of the Skin of Color Clinic because of her dedication to providing personalized care for patients of all ethnicities, skin tones and hair textures,” Dr. Ida Orengo, professor and chair of dermatology at Baylor, adds. “The Skin of Color clinic will focus on the treatment of the diverse complexions of our patients and address the gaps in treatment while aiming to correct disparities and help ensure inclusivity in Houston healthcare.”

To further address those disparities, Dr. Oyerinde is planning community outreach events for potential Houston-area patients who may be unaware that clinics like this exist.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

How Houston's innovation sector fared in 2025 Texas legislative session

That's a Wrap

The Greater Houston Partnership is touting a number of victories during the recently concluded Texas legislative session that will or could benefit the Houston area. They range from billions of dollars for dementia research to millions of dollars for energy projects.

“These wins were only possible through deep collaboration, among our coalition partners, elected officials, business and community leaders, and the engaged members of the Partnership,” according to a partnership blog post. “Together, we’ve demonstrated how a united voice for Houston helps drive results that benefit all Texans.”

In terms of business innovation, legislators carved out $715 million for nuclear, semiconductor, and other economic development projects, and a potential $1 billion pool of tax incentives through 2029 to support research-and-development projects. The partnership said these investments “position Houston and Texas for long-term growth.”

Dementia institute

One of the biggest legislative wins cited by the Greater Houston Partnership was passage of legislation sponsored by Sen. Joan Huffman, a Houston Republican, to provide $3 billion in funding over 10 years for the Dementia Prevention and Research Institute of Texas. Voters will be asked in November to vote on a ballot initiative that would set aside $3 billion for the new institute.

The dementia institute would be structured much like the Cancer Prevention and Research Institute of Texas (CPRIT), a state agency that provides funding for cancer research in the Lone Star State. Since its founding in 2008, CPRIT has awarded nearly $3.9 billion in research grants.

“By establishing the Dementia Prevention and Research Institute of Texas, we are positioning our state to lead the charge against one of the most devastating health challenges of our time,” Huffman said. “With $3 billion in funding over the next decade, we will drive critical research, develop new strategies for prevention and treatment, and support our healthcare community. Now, it’s up to voters to ensure this initiative moves forward.”

More than 500,000 Texans suffer from some form of dementia, including Alzheimer’s disease, according to Lt. Gov. Dan Patrick.

“With a steadfast commitment, Texas has the potential to become a world leader in combating [dementia] through the search for effective treatments and, ultimately, a cure,” Patrick said.

Funding for education

In the K-12 sector, lawmakers earmarked an extra $195 million for Houston ISD, $126.7 million for Cypress-Fairbanks ISD, $103.1 million for Katy ISD, $80.6 million for Fort Bend ISD, and $61 million for Aldine ISD, the partnership said.

In higher education, legislators allocated:

     
  • $1.17 billion for the University of Houston College of Medicine, University of Texas Health Science Center at Houston, UT MD Anderson Cancer Center, and Baylor College of Medicine
  • $922 million for the University of Houston System
  • $167 million for Texas Southern University
  • $10 million for the Center for Biotechnology at San Jacinto College.

Infrastructure

In the infrastructure arena, state lawmakers:

     
  • Approved $265 million for Houston-area water and flood mitigation projects, including $100 million for the Lynchburg Pump Station
  • Created the Lake Houston Dredging and Maintenance District
  • Established a fund for the Gulf Coast Protection District to supply $550 million for projects to make the coastline and ship channel more resilient

"Nuclear power renaissance"

House Bill 14 (HB 14) aims to lead a “nuclear power renaissance in the United States,” according to Texas Gov. Greg Abbott’s office. HB 14 establishes the Texas Advanced Nuclear Energy Office, and allocates $350 million for nuclear development and deployment. Two nuclear power plants currently operate in Texas, generating 10 percent of the energy that feeds the Electric Reliability Council Texas (ERCOT) power grid.

“This initiative will also strengthen Texas’ nuclear manufacturing capacity, rebuild a domestic fuel cycle supply chain, and train the future nuclear workforce,” Abbott said in a news release earlier this year.

One of the beneficiaries of Texas’ nuclear push could be Washington, D.C.-based Last Energy, which plans to build 30 micro-nuclear reactors near Abilene to serve power-gobbling data centers across the state. Houston-based Pelican Energy Partners also might be able to take advantage of the legislation after raising a $450 million fund to invest in companies that supply nuclear energy services and equipment.

Reed Clay, president of the Texas Nuclear Alliance, called this legislation “the most important nuclear development program of any state.”

“It is a giant leap forward for Texas and the United States, whose nuclear program was all but dead for decades,” said Clay. “With the passage of HB 14 and associated legislation, Texas is now positioned to lead a nuclear renaissance that is rightly seen as imperative for the energy security and national security of the United States.”

---

A version of this article first appeared on EnergyCapitalHTX.com.

View All Listings